{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:03:33Z","timestamp":1793257413270,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Telix Pharmaceuticals","award":["Telix Pharmaceuticals"],"award-info":[{"award-number":["Telix Pharmaceuticals"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Results from a multinational Phase 3 study demonstrated high accuracy and a favorable safety and tolerability profile of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab PET for detection and characterization of clear cell renal cell carcinoma (ccRCC). However, [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab has not been studied in Chinese patients. In this Phase 1 study, we aimed to evaluate safety and tolerability, radiation and tumor dosimetry, and pharmacokinetics of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab PET in Chinese patients with suspected ccRCC. This study was approved by the Ethics Committee of Beijing Cancer Hospital (2022YW225) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. Ten Chinese patients received 37 MBq (\u00b1 10%; 10mg mass dose) of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab intravenously. Whole-body PET imaging was performed in the supine position at approximately 0.5, 4, 24, 72 hours, and 7 \u00b1 1 days after administration, and low dose CT was used for attenuation correction. Adverse events were recorded from time of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab administration through final visit. Blood samples were collected from patients approximately 1 hour before, and 0.5, 1, 2, 4, 24, 72 hours, and 5 \u00b1 1 days after [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab administration. Biodistribution and normal organ dosimetry were performed based on PET images to determine significant differences in tumor-absorbed dose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 10 adverse events reported, none were serious or considered related to [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab. The organs receiving the highest mean (SD) normalized absorbed doses were the liver (1.51 [0.23] mGy\/MBq), kidneys (1.42 [0.35] mGy\/MBq), and heart wall (1.22 [0.18] mGy\/MBq), with a mean whole-body normalized effective dose of 0.49 (0.08) mSv\/MBq. In 7 patients with histologically confirmed ccRCC, mean (SD) tumor normalized absorbed dose was 2.87 (1.54) mGy\/MBq (range: 1.17 to 5.41 mGy\/MBq).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab has a favorable safety and tolerability profile in Chinese patients, with a dosimetry profile similar to previously studied non-Chinese populations. [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-girentuximab is a promising novel PET agent for the detection and characterization of ccRCC in Chinese patients. Trial registration: ClinicalTrials.gov Identifier NCT05861778. Registered 17 May 2023.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01332-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T22:13:58Z","timestamp":1766614438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of [89Zr]Zr-girentuximab PET imaging of clear cell renal cell carcinoma in Chinese patients: a Phase 1 clinical study (ZIRDOSE-CP)"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1868-8347","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"1","key":"1332_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88682-1","volume":"15","author":"Z Qiao","year":"2025","unstructured":"Qiao Z, Xiong J, Zhang S, Chen L, Wang J, Chen R. A comparative analysis of global and Chinese trends in the burden of kidney cancer from 1990 to 2021. Sci Rep. 2025;15(1):4558.","journal-title":"Sci Rep"},{"issue":"3","key":"1332_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","volume":"16","author":"JJ Ko","year":"2015","unstructured":"Ko JJ, Xie W, Kroeger N, Lee J-l, Rini BI, Knox JJ, et al. The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293\u2013300.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1332_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","volume":"183","author":"BC Leibovich","year":"2010","unstructured":"Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309\u201316.","journal-title":"J Urol"},{"issue":"2","key":"1332_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bju.12950","volume":"117","author":"L Lipworth","year":"2016","unstructured":"Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2016;117(2):260\u20135.","journal-title":"BJU Int"},{"key":"1332_CR5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","volume":"36","author":"AY Warren","year":"2018","unstructured":"Warren AY, Harrison D. WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol. 2018;36:1913\u201326.","journal-title":"World J Urol"},{"key":"1332_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.727778","volume":"11","author":"X Qi","year":"2021","unstructured":"Qi X, Li Q, Che X, Wang Q, Wu G. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in CcRCC. Front Oncol. 2021;11:727778.","journal-title":"Front Oncol"},{"issue":"1","key":"1332_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33375-w","volume":"13","author":"AM Alchahin","year":"2022","unstructured":"Alchahin AM, Mei S, Tsea I, Hirz T, Kfoury Y, Dahl D, et al. A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nat Commun. 2022;13(1):5747.","journal-title":"Nat Commun"},{"issue":"1","key":"1332_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74\u201384.","journal-title":"Eur Urol"},{"issue":"5","key":"1332_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.7150\/jca.105713","volume":"16","author":"S Zou","year":"2025","unstructured":"Zou S, Cui L, Pai P, Lu Y, Li X, Wang G, et al. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: a SEER database analysis. J Cancer. 2025;16(5):1591\u20137.","journal-title":"J Cancer"},{"issue":"6","key":"1332_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2214\/AJR.14.12502","volume":"202","author":"SK Kang","year":"2014","unstructured":"Kang SK, Huang WC, Pandharipande PV, Chandarana H. Solid renal masses: what the numbers tell us. Am J Roentgenol. 2014;202(6):1196\u2013206.","journal-title":"Am J Roentgenol"},{"key":"1332_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.04.019","author":"S Sevcenco","year":"2014","unstructured":"Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol Semin Orig Investig. 2014. https:\/\/doi.org\/10.1016\/j.urolonc.2014.04.019.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"2","key":"1332_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/0970-1591.126900","volume":"30","author":"ND Patel","year":"2014","unstructured":"Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170\u20136.","journal-title":"Indian J Urol"},{"issue":"2","key":"1332_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/JU.0000000000001911","volume":"206","author":"SC Campbell","year":"2021","unstructured":"Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol. 2021;206(2):199\u2013208.","journal-title":"J Urol"},{"issue":"5","key":"1332_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.eururo.2022.01.040","volume":"81","author":"E Roussel","year":"2022","unstructured":"Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur Urol. 2022;81(5):476\u201388.","journal-title":"Eur Urol"},{"issue":"6","key":"1332_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.eururo.2013.02.022","volume":"63","author":"CH Muselaers","year":"2013","unstructured":"Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111\u2013labeled Girentuximab immunospect as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63(6):1101\u20136.","journal-title":"Eur Urol"},{"issue":"3","key":"1332_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","volume":"12","author":"H-Y Wang","year":"2012","unstructured":"Wang H-Y, Ding H-J, Chen J-H, Chao C-H, Lu Y-Y, Lin W-Y, et al. Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET\/CT in renal cell carcinoma. Cancer Imaging. 2012;12(3):464.","journal-title":"Cancer Imaging"},{"issue":"4","key":"1332_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399\u2013410.","journal-title":"Eur Urol"},{"issue":"5","key":"1332_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.eururo.2018.12.011","volume":"75","author":"PS Macklin","year":"2019","unstructured":"Macklin PS, Sullivan ME, Tapping CR, Cranston DW, Webster GM, Roberts IS, et al. Tumour seeding in the tract of percutaneous renal tumour biopsy: a report on seven cases from a UK tertiary referral centre. Eur Urol. 2019;75(5):861\u20137.","journal-title":"Eur Urol"},{"issue":"4","key":"1332_CR19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","volume":"69","author":"L Marconi","year":"2016","unstructured":"Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69(4):660\u201373.","journal-title":"Eur Urol"},{"issue":"5","key":"1332_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.juro.2015.11.029","volume":"195","author":"HD Patel","year":"2016","unstructured":"Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol. 2016;195(5):1340\u20137.","journal-title":"J Urol"},{"issue":"2","key":"1332_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2217\/iim.11.9","volume":"3","author":"T Oei","year":"2011","unstructured":"Oei T, Hedgire S, Harisinghani M. Advanced cross-sectional imaging techniques for the detection and characterization of renal masses. Imaging Med. 2011;3(2):207.","journal-title":"Imaging Med"},{"issue":"6","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.juro.2014.12.021","volume":"193","author":"J Prince","year":"2015","unstructured":"Prince J, Bultman E, Hinshaw L, Drewry A, Blute M, Best S, et al. Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol. 2015;193(6):1899\u2013904.","journal-title":"J Urol"},{"key":"1332_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-016-1017-z","volume":"14","author":"JH Kim","year":"2016","unstructured":"Kim JH, Sun HY, Hwang J, Hong SS, Cho YJ, Doo SW, et al. Diagnostic accuracy of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging of small renal masses in real practice: sensitivity and specificity according to subjective radiologic interpretation. World J Surg Oncol. 2016;14:1\u20138.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"1332_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","volume":"31","author":"L Lindenberg","year":"2019","unstructured":"Lindenberg L, Mena E, Choyke PL, Bouchelouche K. Pet imaging in renal cancer. Curr Opin Oncol. 2019;31(3):216\u201321.","journal-title":"Curr Opin Oncol"},{"key":"1332_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071829","author":"S Muselaers","year":"2022","unstructured":"Muselaers S, Erdem S, Bertolo R, Ingels A, Kara O, Pavan N, et al. PSMA PET\/CT in renal cell carcinoma: an overview of current literature. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11071829.","journal-title":"J Clin Med"},{"issue":"1","key":"1332_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000645","volume":"4","author":"J Weindler","year":"2025","unstructured":"Weindler J, Ali M, Udovicich C, Hofman MS, Siva S. Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma. BMJ Oncol. 2025;4(1):e000645.","journal-title":"BMJ Oncol"},{"issue":"1","key":"1332_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01232-8","volume":"15","author":"S Binzaqr","year":"2025","unstructured":"Binzaqr S, Kryza D, Giraudet AL, Bernhard JC, Gross-Goupil M, Yacoub M, et al. Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study). EJNMMI Res. 2025;15(1):38.","journal-title":"EJNMMI Res"},{"key":"1332_CR28","unstructured":"Davis ID, Wiseman GA, Lee F-T, Gansen DN, Hopkins W, Papenfuss AT et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 2007;7(1)."},{"issue":"1","key":"1332_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","volume":"58","author":"AB Stillebroer","year":"2010","unstructured":"Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58(1):75\u201383.","journal-title":"Eur Urol"},{"key":"1332_CR30","doi-asserted-by":"publisher","unstructured":"Merkx RI, Lobeek D, Konijnenberg M, Jim\u00e9nez-Franco LD, Kluge A, Oosterwijk E, et al. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;(10):9. https:\/\/doi.org\/10.1007\/s00259-021-05271-w.","DOI":"10.1007\/s00259-021-05271-w"},{"key":"1332_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae075","author":"N Nakaigawa","year":"2024","unstructured":"Nakaigawa N, Hasumi H, Utsunomiya D, Yoshida K, Ishiwata Y, Oka T, et al. Evaluation of PET\/CT imaging with [89Zr] Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP). Jpn J Clin Oncol. 2024. https:\/\/doi.org\/10.1093\/jjco\/hyae075.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"1332_CR32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard J-C, Morris MA, Master V, Scott A, et al. [\u2078\u2079Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(10):1277\u201387.","journal-title":"Lancet Oncol"},{"key":"1332_CR33","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Padilla D, Zalabardo DS, Fernando-Valderrama E, Villacampa-Aub\u00e1 F. Initial clinical experience with Zr-Girentuximab PET-CT for evaluation of renal masses in patients with solitary kidneys. Actas Urol Esp. 2025:501691.","DOI":"10.1016\/j.acuroe.2025.501691"},{"issue":"1","key":"1332_CR34","first-page":"1","volume":"51","author":"Medicine EAoN","year":"2024","unstructured":"Medicine EAoN. EANM\u201924 abstract book Congress Oct 19\u201323, 2024. Eur J Nucl Med Mol Imaging. 2024;51(1):1\u20131026.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1332_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","volume":"74","author":"MCH Hekman","year":"2018","unstructured":"Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, et al. Positron emission tomography\/computed tomography with (89)Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol. 2018;74(3):257\u201360.","journal-title":"Eur Urol"},{"issue":"1","key":"1332_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29577-x","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu Y, Feng J, Wu X, Bai L, Xu W, Zhu L, et al. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nat Commun. 2022;13(1):2052.","journal-title":"Nat Commun"},{"issue":"1","key":"1332_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14601-9","volume":"11","author":"X-M Wang","year":"2020","unstructured":"Wang X-M, Lu Y, Song Y-M, Dong J, Li R-Y, Wang G-L, et al. Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. Nat Commun. 2020;11(1):739.","journal-title":"Nat Commun"},{"issue":"1","key":"1332_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6135","volume":"5","author":"G Scelo","year":"2014","unstructured":"Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonz\u00e0lez-Porta M, Wozniak MB, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014;5(1):5135.","journal-title":"Nat Commun"},{"issue":"2","key":"1332_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ki.2008.129","volume":"74","author":"FD Debelle","year":"2008","unstructured":"Debelle FD, Vanherweghem J-L, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158\u201369.","journal-title":"Kidney Int"},{"issue":"6","key":"1332_CR40","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1332_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1332_CR42","first-page":"149","volume":"41","author":"MG Stabin","year":"2000","unstructured":"Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41(1):149\u201360.","journal-title":"J Nucl Med"},{"issue":"4","key":"1332_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/his.14204","volume":"77","author":"N Baniak","year":"2020","unstructured":"Baniak N, Flood TA, Buchanan M, Dal Cin P, Hirsch MS. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology. 2020;77(4):659\u201366.","journal-title":"Histopathology"},{"issue":"4","key":"1332_CR44","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-08-1229","volume":"15","author":"T Klatte","year":"2009","unstructured":"Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1332_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.urolonc.2018.08.015","volume":"36","author":"F Buscheck","year":"2018","unstructured":"Buscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Moller-Koop C, et al. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urol Oncol. 2018;36(12):531. e19- e25.","journal-title":"Urol Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01332-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:46:58Z","timestamp":1781624818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01332-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01332-5","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, China Good Clinical Practice (GCP; 2020 version; GCP registration number of Beijing Cancer Hospital: 2019000050), and the International Conference on Harmonisation E6 guidance for GCP. The study was approved by the Ethics Committee of Beijing Cancer Hospital (2022YW225) prior to initiation. All patients provided written informed consent prior to participation in the study. No study-related procedure was implemented before signed written informed consent forms were obtained from patients or their legally authorized representative(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was sponsored by Telix Pharmaceuticals, with Grand Pharmaceutical (China) as local sponsor. BC and DC are employees of Telix Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}